Posts filed under ‘Infecciones en piel y tej blandos’

Still fighting prosthetic joint infection after knee replacement

LANCET Infectous Diseases June 2019 V.19 N.6

COMMENT – Still fighting prosthetic joint infection after knee replacement

We congratulate Erik Lenguerrand and colleagues on the publication of their paper in The Lancet Infectious Diseases1 and respect that it is a well-conducted study. In their large-scale observational study, the authors collected data from the UK National Joint Registry including a total of 679 010 primary knee arthroplasty cases and evaluated associations between patient, surgical, and healthcare system factors and the risk of revision for prosthetic joint infection. To the best of our knowledge, this is the largest cohort study to date analysing the risk factors for periprosthetic joint infection following primary total knee replacement…

FULL TEXT

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30067-2/fulltext?dgcid=raven_jbs_etoc_email

PDF

https://www.thelancet.com/action/showPdf?pii=S1473-3099%2819%2930067-2

 

 

LANCET Infectous Diseases June 2019 V.19 N.6

Risk factors associated with revision for prosthetic joint infection following knee replacement: an observational cohort study from England and Wales

Background

Prosthetic joint infection is a devastating complication of knee replacement. The risk of developing a prosthetic joint infection is affected by patient, surgical, and health-care system factors. Existing evidence is limited by heterogeneity in populations studied, short follow-up, inadequate power, and does not differentiate early prosthetic joint infection, most likely related to the intervention, from late infection, more likely to occur due to haematogenous bacterial spread. We aimed to assess the overall and time-specific associations of these factors with the risk of revision due to prosthetic joint infection following primary knee replacement.

Methods

In this cohort study, we analysed primary knee replacements done between 2003 and 2013 in England and Wales and the procedures subsequently revised for prosthetic joint infection between 2003 and 2014. Data were obtained from the National Joint Registry linked to the Hospital Episode Statistics data in England and the Patient Episode Database for Wales. Each primary replacement was followed for a minimum of 12 months until the end of the observation period (Dec 31, 2014) or until the date of revision for prosthetic joint infection, revision for another indication, or death (whichever occurred first). We analysed the data using Poisson and piecewise exponential multilevel models to assess the associations between patient, surgical, and health-care system factors and risk of revision for prosthetic joint infection.

Findings

Of 679 010 primary knee replacements done between 2003 and 2013 in England and Wales, 3659 were subsequently revised for an indication of prosthetic joint infection between 2003 and 2014, after a median follow-up of 4·6 years (IQR 2·6–6·9). Male sex (rate ratio [RR] for male vs female patients 1·8 [95% CI 1·7–2·0]), younger age (RR for age ≥80 years vs <60 years 0·5 [0·4–0·6]), higher American Society of Anaesthesiologists [ASA] grade (RR for ASA grade 3–5 vs 1, 1·8 [1·6–2·1]), elevated body-mass index (BMI; RR for BMI ≥30 kg/m2 vs <25 kg/m2 1·5 [1·3–1·6]), chronic pulmonary disease (RR 1·2 [1·1–1·3]), diabetes (RR 1·4 [1·2–1·5]), liver disease (RR 2·2 [1·6–2·9]), connective tissue and rheumatic diseases (RR 1·5 [1·3–1·7]), peripheral vascular disease (RR 1·4 [1·1–1·7]), surgery for trauma (RR 1·9 [1·4–2·6]), previous septic arthritis (RR 4·9 [2·7–7·6]) or inflammatory arthropathy (RR 1·4 [1·2–1·7]), operation under general anaesthesia (RR 1·1 [1·0–1·2]), requirement for tibial bone graft (RR 2·0 [1·3–2·7]), use of posterior stabilised fixed bearing prostheses (RR for posterior stabilised fixed bearing prostheses vs unconstrained fixed bearing prostheses 1·4 [1·3–1·5]) or constrained condylar prostheses (3·5 [2·5–4·7]) were associated with a higher risk of revision for prosthetic joint infection. However, uncemented total, patellofemoral, or unicondylar knee replacement (RR for uncemented vs cemented total knee replacement 0·7 [95% CI 0·6–0·8], RR for patellofemoral vs cemented total knee replacement 0·3 [0·2–0·5], and RR for unicondylar vs cemented total knee replacement 0·5 [0·5–0·6]) were associated with lower risk of revision for prosthetic joint infection. Most of these factors had time-specific effects, depending on the time period post-surgery.

Interpretation

We have identified several risk factors for revision for prosthetic joint infection following knee replacement. Some of these factors are modifiable, and the use of targeted interventions or strategies could lead to a reduced risk of revision for prosthetic joint infection. Non-modifiable factors and the time-specific nature of the effects we have observed will allow clinicians to appropriately counsel patients preoperatively and tailor follow-up regimens.

Funding

National Institute for Health Research.

FULL TEXT

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30755- 2/fulltext?dgcid=raven_jbs_etoc_email

PDF

https://www.thelancet.com/action/showPdf?pii=S1473-3099%2818%2930755-2

Advertisements

May 24, 2019 at 7:39 am

Imported toxin-producing cutaneous diphtheria— Minnesota, Washington, and New Mexico, 2015–2018.

MMWR Morb Mortal Wkly Rep March 29, 2019 V.68 N.12 P.281-284

Griffith J et al.

Summary

What is already known about this topic?

Cutaneous diphtheria has not been notifiable in the United States since 1980, and U.S. disease incidence data are limited.

What is added by this report?

Toxin-producing Corynebacterium diphtheriae was identified in cutaneous wounds from four U.S. residents after return from international travel. Public health response for toxin-producing diphtheria includes treating patients, providing chemoprophylaxis to close contacts, testing patients and close contacts for C. diphtheriae carriage, and providing diphtheria toxoid–containing vaccine to incompletely immunized patients and close contacts.

What are the implications for public health practice?

Cutaneous toxin-producing diphtheria should be considered in travelers with wound infections who have returned from countries with endemic disease to permit prompt public health response and prevent disease transmission.

 

From September 2015 to March 2018, CDC confirmed four cases of cutaneous diphtheria caused by toxin-producing Corynebacterium diphtheriae in patients from Minnesota (two), Washington (one), and New Mexico (one). All patients had recently returned to the United States after travel to countries where diphtheria is endemic. C. diphtheriae infection was not clinically suspected in any of the patients; treating institutions detected the organism through matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF) testing of wound-derived coryneform isolates. MALDI-TOF is a rapid screening platform that uses mass spectrometry to identify bacterial pathogens. State public health laboratories confirmed C. diphtheriae through culture and sent isolates to CDC’s Pertussis and Diphtheria Laboratory for biotyping, polymerase chain reaction (PCR) testing, and toxin production testing. All isolates were identified as toxin-producing C. diphtheriae. The recommended public health response for cutaneous diphtheria is similar to that for respiratory diphtheria and includes treating the index patient with antibiotics, identifying close contacts and observing them for development of diphtheria, providing chemoprophylaxis to close contacts, testing patients and close contacts for C. diphtheriae carriage in the nose and throat, and providing diphtheria toxoid–containing vaccine to incompletely immunized patients and close contacts. This report summarizes the patient clinical information and response efforts conducted by the Minnesota, Washington, and New Mexico state health departments and CDC and emphasizes that health care providers should consider cutaneous diphtheria as a diagnosis in travelers with wound infections who have returned from countries with endemic diphtheria.

FULL TEXT

https://www.cdc.gov/mmwr/volumes/68/wr/mm6812a2.htm?s_cid=mm6812a2_w

PDF

https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6812a2-H.pdf

April 18, 2019 at 9:57 am

Chile: Primer reporte de colonización por Candida auris uris en un paciente procedente de India

Sociedad Chilena de Infectología

Microbiólogos e infectólogos del Hospital del Salvador, de Santiago, reportaron el 1er aislamiento en Chile de Candida auris en un paciente de nacionalidad india y radicado en Chile hace 30 años. El paciente es diabético tipo II de larga data.

En agosto 2018 evolucionó con signos de isquemia y posteriormente necrosis del 4to dedo izquierdo asociado a celulitis del mismo pie.

Sus familiares decidieron el traslado a Mumbay (India), para su tratamiento.

Fue amputado en un hospital en Mumbay el 20/agosto/2018. Completó 24 días de hospitalización por dificultad en el manejo de su diabetes mellitus, y posteriormente continuó con curaciones ambulatorias en el mismo centro.

Una semana antes de volver a Chile, en octubre 2018, notó signos compatibles con necrosis en la falange distal del 3er dedo ipsilateral.

Consultó a su regreso a Chile en el Servicio de Urgencia de un centro privado. Fue derivado al Hospital del Salvador, donde se estudió y derivó a cirugía vascular para amputación del 3er y 5to dedos  izquierdos con diagnóstico de pie diabético con complicaciones vasculares, sin signos de infección.

El 26/diciembre/2018 ingresó a pabellón, donde se tomaron cultivos de tejido del lecho de amputación y de una úlcera plantar en relación a la base del 5to dedo.

Luego de 48 hs de incubación no hubo crecimiento de colonias en el cultivo corriente, por lo que se realizó un traspaso final desde el caldo tioglicolato a un agar sangre.

El 31/12/2018 se estudió una colonia blanca pequeña, la que es identificada como Kokuria kristinae (98% de concordancia). Se realizó tinción de Gram de dicha colonia, observándose levaduras.

El 2/enero/2019 se procesó nuevamente, dando como resultado C. auris con 99% de concordancia.

En función de los resultados obtenidos, se envió la cepa al Instituto de Salud Pública (ISP), quien el 17/enero/2019 confirmó la identificación.

El paciente no fue tratado con antifúngicos debido a que este hallazgo fue interpretado como una colonización, al no existir síntomas ni signos inflamatorios en el sitio quirúrgico.

En controles posteriores, un mes después de la amputación, se evidenciaron elementos compatibles con infección del sitio quirúrgico (ISQ) realizándose toilette de la zona en la cual se aislaron Klebsiella pneumoniae (en tejido óseo y partes blandas) y Staphylococcus aureus (partes blandas), pero no se ha vuelto a aislar C. auris en muestras de tejido y hueso del paciente.

Producto del patrón de susceptibilidad de los agentes identificados, se hospitalizó para tratamiento ATB IV, siendo sometido finalmente a una amputación trans-metatarsiana el 19/febrero/2019.

En dicho procedimiento se tomaron cultivos óseos y de tejidos blandos adyacentes con resultados negativos.

Durante esta hospitalización, se obtuvieron hisopados nasal, orofaríngeo, axilar e inguinorrectal para estudio de portación de C. auris, con resultados negativos.

Para los procesos de atención clínica, el paciente fue manejado con precauciones de contacto (unidad individual, uso de elementos de protección personal, aseo de unidad supervisado de acuerdo a protocolo interno).

Candida auris es un hongo emergente considerado una seria amenaza para la salud pública. La preocupación mundial por C. auris se debe principalmente a tres razones:

1) la resistencia que presenta a múltiples antifúngicos comúnmente utilizados para tratar las infecciones por Candida;

2) los errores en la identificación con los métodos de laboratorio estándar;

3) ser causa de brotes intrahospitalarios en los cinco continentes.

Por esta razón, es importante identificar rápidamente la presencia de C. auris en un paciente hospitalizado, para que se puedan tomar las precauciones especiales para detener su propagación. Dado el gran potencial de diseminación de esta Candida, es muy importante reforzar las medidas de control para reducir el riesgo de transmisión.

Fuente:

Primer reporte en Chile de colonización por Candida auris en un paciente procedente de India.

Sociedad Chilena de Infectología (Chile)

PDF

http://www.sochinf.cl/portal/templates/sochinf2008/documentos/2019/Primer_reporte_Chile_colonizacion_Candida_auris_India.pdf

April 15, 2019 at 8:35 am

Osteomyelitis Complicating Sacral Pressure Ulcers: Whether or Not to Treat With Antibiotic Therapy

Clinical Infectious Diseases January 15, 2019 V.68 N.2 P.338–342

EDITOR’S CHOICE

Darren Wong; Paul Holtom; Brad Spellberg

The treatment of osteomyelitis in patients with stage IV sacral pressure ulcers is controversial. We conducted a systematic literature review and did not find evidence of benefit of antibacterial therapy in this setting without concomitant surgical debridement and wound coverage. Furthermore, many patients with chronically exposed bone do not have evidence of osteomyelitis when biopsied, and magnetic resonance imaging may not accurately distinguish osteomyelitis from bone remodeling. The goal of therapy should be local wound care and assessment for the potential of wound closure. If the wound can be closed and osteomyelitis is present on bone biopsy, appropriate antibiotic therapy is reasonable. We find no data to support antibiotic durations of >6 weeks in this setting, and some authors recommend 2 weeks of therapy if the osteomyelitis is limited to cortical bone. If the wound will not be closed, we find no clear evidence supporting a role for antibiotic therapy.

FULL TEXT

https://academic.oup.com/cid/article/68/2/338/5050260

PDF (CLIC en PDF)

January 20, 2019 at 11:03 am

Review – Vibrio vulnificus, an important cause of severe sepsis and skin and soft-tissue infection.

International Journal of Infectious Diseases 2011 V.15 e157-e166

Michael A. Horseman a,b,c,*, Salim Surani c,d,e

aDepartment of Pharmacy Practice, College of Pharmacy, Texas A&M Health Sciences Center, Kingsville, Texas, USA

bDepartment of Family Medicine & Community Medicine, School of Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA

c Christus Spohn Hospital Corpus Christi – Memorial, 2606 Hospital Blvd, Corpus Christi, Texas 78405, USA

dDepartment of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas, USA

eDepartment of Internal Medicine, Texas A&M Health Science Center – College of Medicine, Scott and White Hospital, Temple, Texas, USA

Vibrio vulnificus is a halophilic Gram-negative bacillus found worldwide in warm coastal waters.

The pathogen has the ability to cause primary sepsis in certain high-risk populations, including patients with chronic liver disease, immunodeficiency, iron storage disorders, end-stage renal disease, and diabetes mellitus.

Most reported cases of primary sepsis in the USA are associated with the ingestion of raw or undercooked oysters harvested from the Gulf Coast.

The mortality rate for patients with severe sepsis is high, exceeding 50% in most reported series.

Other clinical presentations include wound infection and gastroenteritis.

Mild to moderate wound infection and gastroenteritis may occur in patients without obvious risk factors.

Severe wound infection is often characterized by necrotizing skin and soft-tissue infection, including fasciitis and gangrene.

V. vulnificus possesses several virulence factors, including the ability to evade destruction by stomach acid, capsular polysaccharide, lipopolysaccharide, cytotoxins, pili, and flagellum.

The preferred antimicrobial therapy is doxycycline in combination with ceftazidime and surgery for necrotizing soft-tissue infection.

PDF

https://www.ijidonline.com/article/S1201-9712(10)02538-5/pdf

January 10, 2019 at 8:32 am

Vibrio vulnificus, una bacteria al acecho en las playas.

Highlights en investigación December 2014

Iván Renato Zúñiga Carrasco*, Janett Caro Lozano**.

*Jefe del Departamento de Epidemiología. Miembro del Comité Local de

Investigación y Ética en Salud (CLIES). H.G.Z. # 18 IMSS Playa del Carmen, Quintana

Roo.

**Jefa del Departamento de Epidemiología. Miembro del Comité Local de

Investigación y Ética en Salud (CLIES) H.G.Z. C/M.F. 1 IMSS Chetumal, Quintana Roo.

Un patógeno que puede ser transmitido por los ostiones es Vibrio vulnificus.

Descrito en 1976, se le denominó “Vibrio lactosa positivo”, posteriormente se le llamó Beneckea vulnificus y finalmente V. vulnificus. Pertenece a la familia Vibrionaceae, son bacilos Gramnegativos, rectos y curvos, móviles por la presencia de un flagelo polar, oxidasa positivos, no esporulados.

Son termolábiles y se comportan como anaerobios facultativos.

Entre las más de 30 especies del género Vibrio, se han reportado 12 como patógenas para el hombre, entre las que sobresalen V. cholerae, V. parahaemolyticus y V vulnificus . . .

PDF

http://www.medigraphic.com/pdfs/revenfinfped/eip-2014/eip144e.pdf

January 10, 2019 at 8:30 am

CASO CLINICO – Shock séptico por Vibrio vulnificus – un caso pediátrico

Revista de Enfermedades Infecciosas en Pediatría Diciembre 2013 Vol. XXVII Núm. 106

Dra. Marisol Fonseca Flores*, Dra. Sandra Luz Lizárraga López**, Dr. Agustín De Colsa Ranero***

* Médico Residente de Pediatría. Instituto Nacional de Pediatría.

** Médico Adscrito a la Unidad de Terapia Intensiva. Instituto Nacional de Pediatría.

*** Médico Adscrito al Departamento de Infectología Pediátrica. Instituto Nacional de Pediatría.

Los reportes de infección por V. vulnificus en pediatría son limitados en la literatura, y característicamente se describen 3 cuadros clínicos: Sepsis Primaria, Infección de piel y tejidos blandos e Infección gastrointestinal.

Se reporta el caso de un paciente masculino de 15 años de edad con diagnóstico de aplasia pura de serie roja y hemosiderosis, quien ingresa con cuadro febril, lesiones dérmicas, diarrea y datos de choque.

A los 4 días de su ingreso se identifica Vibrio vulnificus en hemocultivo, sin embargo, el paciente fallece a pesar del tratamiento establecido.

Con la presentación de este caso, se describen las características clínicas, epidemiológicas, factores de riesgos y evolución de la infección sistémica por V. vulnificus . . .

PDF

http://www.medigraphic.com/pdfs/revenfinfped/eip-2013/eip134g.pdf

 

January 10, 2019 at 8:28 am

Older Posts


Calendar

May 2019
M T W T F S S
« Apr    
 12345
6789101112
13141516171819
20212223242526
2728293031  

Posts by Month

Posts by Category